Not all fat is the same
The body stores fat in two functionally different compartments. Subcutaneous fat sits just beneath the skin — the fat you can pinch on your arms, hips, and thighs. Visceral fat sits deep in the abdominal cavity, packed around the liver, pancreas, kidneys, and intestines, infiltrating the heart, and lining the major blood vessels.
Subcutaneous fat is metabolically quiet. It's not great in excess, but it isn't dangerous in moderate amounts. Visceral fat is metabolically active — and what it produces is, biologically, an inflammatory organ that drives nearly every chronic disease we treat downstream.
This distinction is why two people can wear the same clothing size and have radically different cardiovascular risk. It is also why "TOFI" — thin on the outside, fat on the inside — is a real and dangerous phenotype.
What visceral fat actually does to you
01 · Insulin resistance
It blocks your blood sugar control
Visceral fat releases free fatty acids directly into the portal vein, where they reach the liver in high concentration. The liver responds by overproducing glucose and resisting insulin. This is the core upstream lesion in type 2 diabetes — and it starts years before fasting glucose ever rises.
02 · Chronic inflammation
It runs a low-grade fire inside you
Visceral fat continuously secretes inflammatory cytokines — TNF-α, IL-6, CRP — that elevate systemic inflammation. This drives atherosclerosis, joint degeneration, cancer risk, and accelerated aging at the cellular level.
03 · Cardiovascular disease
It builds plaque from the inside out
Visceral adiposity is more tightly correlated with coronary artery disease and stroke than BMI is. Pericardial fat — visceral fat directly around the heart — independently predicts arrhythmia, heart failure, and cardiovascular mortality.
04 · Fatty liver
It fills your liver with fat
MASLD (formerly NAFLD) now affects roughly 30% of American adults and is the fastest-rising indication for liver transplant in the country. Its single biggest driver is visceral adiposity.
05 · Dementia risk
It accelerates cognitive decline
Higher visceral fat in midlife is independently associated with smaller brain volume, more white matter lesions, and increased Alzheimer's risk decades later. Insulin resistance in the brain — sometimes called 'type 3 diabetes' — is part of the mechanism.
Why you can be lean and still have it
The most uncomfortable part of the visceral fat story is that your body weight, BMI, and even your appearance are unreliable indicators. About 25% of people with a "normal" BMI have a dangerously high visceral fat load — sometimes called the normal-weight obese phenotype. These patients carry the metabolic risk of someone much heavier while flying under the radar of standard screening.
This is why we measure visceral fat directly. The scale isn't telling you the truth. Body composition is.
What measurably reduces it
Lever 01
Calorie deficit — but carefully
Visceral fat is, fortunately, the first fat the body mobilizes during weight loss. A modest, sustained calorie deficit reliably reduces it. The trap is doing it so aggressively that you lose muscle — which slows your metabolism and rebounds the loss.
Lever 02
GLP-1 medications, used correctly
GLP-1 medications reduce visceral fat significantly — often more than subcutaneous fat — by lowering caloric intake and improving insulin sensitivity. Used without medical supervision and without a protein/resistance protocol, they also strip 25–40% of lost weight from muscle. Supervised, they're one of the most powerful tools we have.
Lever 03
Resistance training
Muscle is the largest insulin sink in the body. Adding lean mass directly improves insulin sensitivity, which improves the body's ability to mobilize and burn visceral fat. Cardio helps; lifting is non-negotiable.
Lever 04
Sleep and stress
Cortisol is one of the strongest visceral-fat-depositing signals in the body. Chronic short sleep (under 6 hours) and chronic stress reliably increase visceral fat — even in the absence of weight gain. Sleep is metabolic medicine.
Lever 05
Hormone optimization
Estradiol decline at menopause is associated with a clear shift of body fat from subcutaneous to visceral compartments — the so-called 'menopause belly.' Testosterone deficiency in men similarly favors visceral adiposity. Correcting the underlying hormonal driver makes every other lever work better.
Lever 06
Targeted device therapy
Emsculpt NEO uniquely combines radiofrequency-induced subcutaneous fat reduction with deep muscle stimulation — preserving and building the muscle that drives insulin sensitivity while reducing the fat the body has stored. It does not directly remove visceral fat, but it changes the metabolic environment that produces it.
What we actually measure — and why
Standard primary care rarely measures visceral fat. We do — because what gets measured changes. Body composition analysis breaks down lean mass, subcutaneous fat, and visceral fat separately. Hormone panels tell us why the body is depositing fat where it is. Fasting insulin, A1c, hsCRP, and the TG/HDL ratio tell us how much metabolic damage is in motion.
The protocol then becomes obvious. The wins become trackable. And the patient stops chasing the scale and starts watching the metrics that actually predict how long they'll live.
Selected references
- Després JP. Body Fat Distribution and Risk of Cardiovascular Disease. Circulation, 2012.
- Neeland IJ, et al. Visceral and Ectopic Fat, Atherosclerosis, and Cardiometabolic Disease. Lancet Diabetes & Endocrinology, 2019.
- Wilding JPH, et al. Once-Weekly GLP-1 Receptor Agonist in Adults with Overweight or Obesity (STEP 1). NEJM, 2021.
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023.
- Pou KM, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation, 2007.
